Validation and commercialization of a novel blood-based, ultra-multiplex Laboratory Developed Test (LDT) for the prediction of cerebral amyloid status before clinical onset of dementia
Validation and commercialization of a novel blood-based, ultra-multiplex Laboratory Developed Test (LDT) for the prediction of cerebral amyloid status before clinical onset of dementia